Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.

Int J Chron Obstruct Pulmon Dis · 2012 · PMC3276256 · PMID 22334768

Europe PMC DOI

hedged sentences

0.0790

closest p · 1.6× alpha

0.0790

boldest claim

The sentences

nominally significantP = 0.079so close (0.05 < p ≤ 0.1)

Comparison of the MF/F 400/10 combination with placebo showed a nominally significant relative reduction of 20.6% in the rate of mild, moderate, or severe exacerbations ( P = 0.079).

also in 7,732 other papers

marginally significantP = 0.079so close (0.05 < p ≤ 0.1)

Subjects treated with MF/F 400/10 had the lowest rate of mild, moderate, or severe COPD exacerbations across treatments (25.8%), the relative reduction over placebo (20.6%) being nominally marginally significant ( P = 0.079).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.